The FDA has approved Admelog (Sanofi-Adventis), the first copycat version of short-acting insulin lispro (Humalog, Eli Lilly)  to treat individuals age 3 years and older with type 1 diabetes and adults with type 2 diabetes. The product is approved for use as an injection, via pump, or intravenously. It will be available both in vials and as a prefilled pen (Admelog SoloStar).